Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis
| Autor: | Eleanor Schaefer, E. Anne MacGregor, Ying Zhang, Dominique Valade, Jeffrey L. Seeburger, Nancy Strickler, Kathryn M. Connor, Yang Ge, Paul Winner, Tony W. Ho, Carolyn M. Hustad, Roger Cady |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Topiramate
Adult Male Time Factors Adolescent Migraine Disorders Population Triptans Fructose Placebo Severity of Illness Index Disability Evaluation Young Adult Double-Blind Method medicine Humans Functional ability Prospective Studies education Aged Pain Measurement education.field_of_study business.industry Middle Aged Triazoles medicine.disease Rizatriptan Tryptamines Serotonin Receptor Agonists Neuroprotective Agents Treatment Outcome Neurology Migraine Tolerability Anesthesia Acute Disease Female Neurology (clinical) business medicine.drug |
| Zdroj: | Headache. 52(1) |
| ISSN: | 1526-4610 |
| Popis: | Objective.— To assess efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treatment of acute migraine in patients using topiramate for migraine prophylaxis. Background.— There are limited data from prospective controlled trials demonstrating the benefit of triptans in patients who experience migraine attacks while taking prophylactic medication. Methods.— This was a worldwide, randomized, placebo-controlled, double-blind, multiple-attack study in adults with a >1-year history of migraine taking a stable dose of topiramate for migraine prophylaxis and experiencing ≥2 moderate/severe attacks per month. Participants treated 3 moderate/severe attacks in crossover fashion (2 with rizatriptan 10-mg ODT, 1 with placebo) following random assignment to 1 of 3 treatment sequences. The primary end point was 2-hour pain relief. Results.— Two-hour pain relief was significantly greater with rizatriptan compared with placebo (55.0% vs 17.4%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text